Literature DB >> 8289798

Physical and functional interaction between wild-type p53 and mdm2 proteins.

D S Haines1, J E Landers, L J Engle, D L George.   

Abstract

The mdm2 oncogene, which is often amplified in mammalian tumors, produces a number of transcripts that encode distinct protein forms. Previous studies demonstrating that overexpression of the mdm2 gene can activate its transforming potential, and can inhibit the transcriptional activation function of p53, prompted us to begin to explore possible functional differences among the various mdm2 products. Utilizing a transient transfection assay, we have evaluated four naturally occurring murine mdm2 forms for their ability to inhibit p53-mediated transcriptional activation of reporter genes regulated by p53 response elements. Three of these mdm2 forms were found to physically associate with the wild-type p53 protein and to possess the ability to inhibit its transactivation function. A fourth form failed to exhibit either of these functions. This last mdm2 form lacks the N-terminal protein domain that is present in the other three splice forms examined, pointing to this region as one that is critical for complex formation with the p53 protein. Identifying such differences among mdm2 proteins provides important clues for dissecting their functional domains, and emphasizes that defining the individual properties of these products will be critical in elucidating the overall growth control function of the mdm2 gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289798      PMCID: PMC358473          DOI: 10.1128/mcb.14.2.1171-1178.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

2.  Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.

Authors:  D C Olson; V Marechal; J Momand; J Chen; C Romocki; A J Levine
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

3.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

4.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

6.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

7.  Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53.

Authors:  A Otto; W Deppert
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

8.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

View more
  37 in total

1.  pRB induces Sp1 activity by relieving inhibition mediated by MDM2.

Authors:  T Johnson-Pais; C Degnin; M J Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 2.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

5.  Regulation of p53 and MDM2 activity by MTBP.

Authors:  Mark Brady; Nikolina Vlatkovic; Mark T Boyd
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

6.  MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection.

Authors:  W Henning; G Rohaly; T Kolzau; U Knippschild; H Maacke; W Deppert
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Authors:  M J Pykett; J Landers; D L George
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

8.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

Authors:  S N Jones; A R Hancock; H Vogel; L A Donehower; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

9.  The Mdm2 oncoprotein interacts with the cell fate regulator Numb.

Authors:  T Juven-Gershon; O Shifman; T Unger; A Elkeles; Y Haupt; M Oren
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.

Authors:  V Gorgoulis; V Zoumpourlis; G Rassidakis; A Karameris; C Barbatis; D A Spandidos; C Kittas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.